CNR2 functional variant (Q63R) influences childhood immune thrombocytopenic purpura

Haematologica

Volumn 96, Issue 12, 2011, Pages 1883-1885

  Rossi, Francesca ^a   Mancusi, Silvia ^a   Bellini, Giulia ^a   Roberti, Domenico ^a   Punzo, Francesca ^a   Vetrella, Simona ^a   Matarese, Sofia Maria Rosaria ^a   Nobili, Bruno ^a   Maione, Sabatino ^a   Perrotta, Silverio ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Cannabinoid receptor; CB2; Children; Endocannabinoid system; Immune thrombocytopenic purpura

Indexed keywords

CANNABINOID 2 RECEPTOR; GENOMIC DNA;

ADOLESCENT; ARTICLE; CASE CONTROL STUDY; CHILD; CNR2 GENE; CONTROLLED STUDY; FEMALE; GENE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HIGH RISK POPULATION; HOMOZYGOTE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFANT; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; SCHOOL CHILD;

ACUTE DISEASE; ADOLESCENT; ALLELES; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INFANT; MUTATION, MISSENSE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTOR, CANNABINOID, CB2;

EID: 82855168097     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.045732     Document Type: Article

References (21)

1. Cooper N, Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematologica. 2006;133(4):364-374.
2. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113(26):6511-6521.
3. Bergmann AK, Grace RF, Neufeld EJ. Genetic studies in pediatric ITP: outlook, feasibility, and requirements. Ann Hematol. 2010;89 (Suppl 1):S95-S103.
4. Breunis WB, van Mirre E, Bruin M, Geissler J, de Boer M, Peters M, et al. Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. Blood. 2008;111(3):1029-1038.
5. Kuwana M, Ikeda Y. The role of autoreactive T-cells in the pathogenesis of idiopathic thrombocytopenic purpura. Int J Hematol. 2005;81(2):106-112.
6. Ouzaki A, Theodoropoulou M, Gianakopoulos I, Vlaha V, Kyrtsonis MC, Maniatis A. Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP) at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment: their role in prognosis. Blood. 2002;100(5):1774-1779.
7. Wang T, Zhao H, Ren H, Guo J, Xu M, Yang R, et al. Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Haematologica. 2005;90(7):914-923.
8. Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995;232(1):54-61.
9. Cabral GA and Griffin-Thomas L. Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev Mol Med. 2009;11:e3.
10. Cencioni MT, Chiurchiù V, Catanzaro G, Borsellino G, Bernardi G, Battistini L, et al. Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS One. 2010;5(1):e8688.
11. Osawa K, Takami N, Shiozawa K, Hashiramoto A, Shiozawa S. Death receptor 3 (DR3) gene duplication in a chromosome region 1p36.3: gene duplication is more prevalent in rheumatoid arthritis. Genes Immun. 2004;5(6):439-443.
12. Shai R, Quismorio FP Jr, Li L, Kwon OJ, Morrison J, Wallace DJ, et al. Genome-wide screen for systemic lupus erythematosus susceptibility genes in multiplex families. Hum Mol Genet. 1999;8(4):639-644.
13. Nishimura M, Obayashi H, Mizuta I, Hara H, Adachi T, Ohta M, et al. TNF, TNF Receptor Type 1, and Allograft Inflammatory Factor-1 Gene Polymorphisms in Japanese Patients With Type 1. Diab Hum Immunol. 2003;64 (2):302-309.
14. George JN, Woolf SH, Raskob GE. Idiopathic thrombocytopenic purpura: a guideline for diagnosis and management of children and adults. American Society of Hematology. Ann Med. 1998;30(1):38-44.
15. De Mattia D, Del Principe D, Del Vecchio GC, Jankovic M, Arrighini A, Giordano P, et al. Acute childhood idiopathic thrombocytopenic purpura: AIEOP consensus guidelines for diagnosis and treatment. Associazione Italiana di Ematologia e Oncologia Pediatrica. Haematologica. 2000;85 (4):420-424.
16. De Mattia D, Del Vecchio GC, Russo G, De Santis A, Ramenghi U, Notarangelo L, et al. AIEOP-ITP Study Group. Management of chronic childhood immune thrombocytopenic purpura: AIEOP consensus guidelines. Acta Haematol. 2010;123(2):96-109.
17. Onaivi ES, Ishiguro H, Gong JP, Patel S, Meozzi PA, Myers L, et al. Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann NY Acad Sci. 2008;1139:434-449.
18. Rieder SA, Chauhan A, Singh U, Nagarkatti M, Nagarkatti P. Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology. 2010; 215(8):598-605.
19. Börner C, Smida M, Höllt V, Schraven B, Kraus J. Cannabinoid receptor type 1- and 2- mediated increase in cyclic AMP inhibits T cell receptor-triggered signaling. J Biol Chem. 2009;284(51):35450-35460.
20. Tschop J, Kasten KR, Nogueiras R, Goetzman HS, Cave CM, England LG, et al. The cannabinoid receptor 2 is critical for the host response to sepsis. Immunol. 2009;183(1): 499-505.
21. Sipe JC, Arbour N, Gerber A, Beutler E. Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: possible risk for autoimmune disorders. J Leukoc Biol. 2005;78(1):231-238.